CUTANEOUS T CELL LYMPHOMA
Clinical trials for CUTANEOUS T CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CUTANEOUS T CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for CUTANEOUS T CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Real-World study confirms Mogamulizumab's effectiveness against rare skin cancer
Disease control CompletedThis study looked at 100 adults with cutaneous T-cell lymphoma (a rare type of skin cancer) who had already tried at least one other treatment. Researchers wanted to see how well the drug mogamulizumab works in everyday medical practice, not just in controlled trials. They measur…
Matched conditions: CUTANEOUS T CELL LYMPHOMA
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Light-Activated ointment shows promise for rare skin cancer
Disease control CompletedThis study tested a synthetic ointment (HyBryte) activated by visible light to treat mycosis fungoides, a type of skin lymphoma. Ten adults with early-stage disease received treatment for up to 54 weeks. The goal was to see if the ointment could reduce redness, scaling, and plaqu…
Matched conditions: CUTANEOUS T CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Ellen Kim, MD • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug cocktail shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-phase trial tested a combination of four drugs (romidepsin, CC-486, dexamethasone, and lenalidomide) in 26 adults with T-cell cancers that had returned or stopped responding to prior treatments. The main goal was to find a safe dose and check for side effects. While th…
Matched conditions: CUTANEOUS T CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental combo aims to boost stem cell transplant for rare blood cancers
Disease control CompletedThis early-phase trial tested whether adding the drug romidepsin before and after a stem cell transplant could help control T-cell cancers like lymphoma and leukemia. Twenty-three patients received romidepsin along with standard chemotherapy, followed by a donor stem cell transpl…
Matched conditions: CUTANEOUS T CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 18:59 UTC